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A retrospective analysis of survival and prognostic
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Abstract
Background: While most meningiomas are benign, aggressive meningiomas are associated with high levels of
recurrence and mortality. A single institution’s Gamma Knife radiosurgical experience with atypical and malignant
meningiomas is presented, stratified by the most recent WHO classification.
Methods: Thirty-one patients with atypical and 4 patients with malignant meningiomas treated with Gamma Knife
radiosurgery between July 2000 and July 2011 were retrospectively reviewed. All patients underwent prior surgical
resection. Overall survival was the primary endpoint and rate of disease recurrence in the brain was a secondary
endpoint. Patients who had previous radiotherapy or prior surgical resection were included. Kaplan-Meier and Cox
proportional hazards models were used to estimate survival and identify factors predictive of recurrence and survival.
Results: Post-Gamma Knife recurrence was identified in 11 patients (31.4%) with a median overall survival of 36 months
and progression-free survival of 25.8 months. Nine patients (25.7%) had died. Three-year overall survival (OS) and
progression-free survival (PFS) rates were 78.0% and 65.0%, respectively. WHO grade II 3-year OS and PFS were 83.4%
and 70.1%, while WHO grade III 3-year OS and PFS were 33.3% and 0%. Recurrence rate was significantly higher in
patients with a prior history of benign meningioma, nuclear atypia, high mitotic rate, spontaneous necrosis, and WHO
grade III diagnosis on univariate analysis; only WHO grade III diagnosis was significant on multivariate analysis. Overall
survival was adversely affected in patients with WHO grade III diagnosis, prior history of benign meningioma, prior
fractionated radiotherapy, larger tumor volume, and higher isocenter number on univariate analysis; WHO grade III
diagnosis and larger treated tumor volume were significant on multivariate analysis.
Conclusion: Atypical and anaplastic meningiomas remain difficult tumors to treat. WHO grade III diagnosis and treated
tumor volume were significantly predictive of recurrence and survival on multivariate analysis in aggressive
meningioma patients treated with radiosurgery. Larger tumor size predicts poor survival, while nuclear atypia, necrosis,
and increased mitotic rate are risk factors for recurrence. Clinical and pathologic predictors may help identify patients
that are at higher risk for recurrence.
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Background
Meningiomas are tumors of the meninges, the membranes
overlying the brain and spinal cord. They are derived from
arachnoid cap cells, which are cytologically similar to
meningioma tumor cells [1,2]. Intracranial meningiomas
account for 24-33% of primary brain tumors [3,4] and
have an incidence rate of 6 per 100,000 people per year
[4]. In the absence of genetic or environmental risk fac-
tors, meningiomas occur primarily in the 6th to 8th de-
cades of life [1,5,6]. Meningiomas are more common in
females by a ratio of 2:1 [7]. Common presenting symp-
toms include headache and seizures.
Meningiomas are classified by the World Health
Organization based on morphology on a scale of I-III.
Eighty to ninety percent are benign (WHO Grade I).
Five to twenty percent are atypical (WHO Grade II) and
1-5% are anaplastic or malignant (WHO Grade III)
[8-12].
WHO grade II and III tumors are considered aggressive.
While relatively rare, they are much more difficult to treat
than benign meningiomas. According to current guide-
lines, WHO grade II meningiomas have increased mitotic
activity (≥4 mitoses per high powered field), or at least
three of the following traits: prominent nucleoli, increased
cellularity, small cells with a high nuclear to cytoplasmic
ratio, foci of spontaneous or geographic necrosis, and un-
interrupted patternless or sheet-like growth. Atypical,
chordoid, and clear cell meningiomas are also classified as
WHO grade II. WHO grade III meningiomas have ≥20
mitoses/high-powered field and/or malignant characteris-
tics resembling those of sarcoma, melanoma, or carcin-
oma. Papillary, anaplastic, and rhabdoid meningiomas are
also classified as WHO grade III.
Five- and ten-year overall survival rates for all meningi-
omas are high at 82% and 64% respectively [1], but prog-
nosis for aggressive meningiomas is much worse [13,14].
Survival rates for patients with aggressive meningiomas
are 65% at five years and 51% at ten years [15]. Grade II
and III tumors are more likely to recur and are associated
with worse overall survival. Compared to age and sex
matched benign meningiomas, grade II meningiomas are
approximately 8 times more likely to recur [16]. Further-
more, recurrent meningiomas tend to be more aggressive
than the original [17]. Aggressive meningiomas are more
common among men than women [18].
Adjuvant radiosurgery is increasingly being used after
surgery in the treatment of meningiomas, although a re-
cent study of 228 atypical meningiomas found no differ-
ence in recurrence rates between patients treated with
adjuvant radiosurgery, adjuvant intensity modulated ra-
diation therapy, and surgery alone [19].
Limited data is available regarding treatment outcomes
for patients with aggressive meningiomas treated with
radiosurgery. Additionally, much of the data regarding
treatment for aggressive meningiomas is based on pre-
2000 series. Further information regarding patient char-
acteristics and outcomes is necessary to better guide
management decisions for these patients.
This study reviews the outcomes of 31 grade II and 4
grade III meningioma patients treated with Gamma Knife
radiosurgery at Washington University in St. Louis. Patient
characteristics and previously reported prognostic factors
for disease-free and overall survival are also analyzed.
Methods
Patient selection
Patients with a prior pathologic diagnosis of WHO grade
II–III meningioma treated with Gamma Knife radiosur-
gery at Washington University Medical Center between
July 2000 and July 2011 were retrospectively reviewed.
Our Gamma Knife Unit is a shared community resource
open to qualified neurosurgeons and radiation oncolo-
gists from the greater Saint Louis area. This review was
restricted to patients treated by the neurosurgical and
radiation oncology faculty of the Washington University
School of Medicine. There were no other exclusions.
The main endpoint of the study was overall survival; dis-
ease recurrence in the brain was a secondary endpoint.
Patients who had previous radiotherapy or prior surgical
resection were included. Patients who underwent surgi-
cal resection were medically stable at the time of surgery
and believed to have life expectancies greater than 6
months. Surgical resection was classified by the neuro-
surgeon performing the resection as either a gross-total
resection (GTR) or subtotal resection (STR), or biopsy
only at the time of surgery. WHO Classification is con-
sistent with the most recent WHO 2007 Classification.
Patients were followed serially in both the Neurosurgical
and Radiation Oncology clinics. Washington University
School of Medicine Human Research Protection Office
reviewed and approved this study, IRB ID# 201010707.
Radiosurgical technique
Stereotactic radiosurgery was performed at the Gamma
Knife of Saint Louis facility at Barnes Jewish Hospital/
Washington University Medical Center. All patients under-
went stereotactic radiosurgery using a Gamma Knife unit
(Elekta, Atlanta, GA). From 1998 to August 2002 a Model
B was in operation, while from August 2002 to April 2008
a Model C was used. Currently a Perfexion unit is in use.
All patients had intravenous access placed. A Leksell
frame was placed under local anesthesia often with a low,
intravenous dose of an anxiolytic. In most cases, a contrast
enhanced computed tomography scan and a contrast en-
hanced magnetic resonance image were obtained and im-
ages transferred to the GK treatment-planning computer.
The target(s) were contoured and a radiosurgery plan was
developed. Tumor size, tumor location, and history of
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prior radiation therapy were important factors in selection
of the prescription dose. The prescription dose was typic-
ally prescribed to the 50% isodose line, which followed the
tumor margin. Quality Assurance review consisted of the
following: verification of patient name from all imaging;
verification of patient orientation (visible surface markers
on the patient’s left side and patient anatomy); review of
MR fiducial alignment; verification of patient identity (pa-
tient name and birth date by all members of the treatment
team); as well as verification of the treatment specifica-
tions at the console after transfer by comparison against
the paper treatment plan.
The medical record was retrospectively reviewed to de-
termine pretreatment patient and tumor characteristics
and the dates of time-to-event endpoints. The recurrence
of treated disease, progression of known disease, or the de-
velopment of new brain metastasis was scored as a failure
for brain recurrence. Death from any cause was a failure
for overall survival. All times were measured from the date
of radiosurgery.
Statistical analysis
Standard measures of central tendency and dispersal were
used to characterize patient and tumor parameters. Survival
time and time to CNS recurrence were calculated from the
date of SRS. The Kaplan-Meier method was used to de-
scribe time to brain recurrence and overall survival. The
log-rank test was used to compare these endpoints. The
Cox Proportional Hazards method was used to identify pre-
dictors of overall survival. Based on published literature,
several known predictors such as age, performance status,
and presence of extra-CNS disease were force-entered into
the model. Suspected predictive factors including treatment
intent and number of brain metastases were then entered
using backwards deletion. Statistical tests were performed
using SAS version 9.2 (SAS Institute Inc., Cary, NC). All




Thirty-one patients with atypical and four patients with
malignant meningiomas treated with Gamma Knife stereo-
tactic radiosurgery between 2000 and 2011 were reviewed.
All patients received surgery as their first treatment modal-
ity. A summary of patient characteristics is presented in
Table 1. Eighteen of the patients (51.4%) were male. The
median patient age was 57 years (range: 26 – 81 years) at
surgery, and 61 years (range: 26 – 84 years) at the time of
radiosurgery. Seven tumors were located in the skull base,
16 along the convexity, 11 in the parasagittal/falcine region,
and 1 intraventricular tumor.
Radiosurgical parameters
All patients were treated as described in the methods sec-
tion. The median tumor volume was 3.90 cm3 (range: 0.19-
33.1), as was the median treated tumor volume (range:
0.19-31.9). The median radiosurgical margin dose was
18 Gy (range: 14–24 Gy) with a median of 10 isocenters
(range: 2–49). The median time from surgery to Gamma
Knife radiosurgery was 21.1 months (range: 0.1 – 246
months), and the median follow-up time post-Gamma
Knife was 34.5 months (range: 0 – 117 months).
Table 1 Patient characteristics
Characteristic Median (range) or n(%)
Age at surgery 57 (26–81)







WHO Grade II 31 (88.6%)
WHO Grade III 4 (11.4%)
Risk factors
Hypertension 9 (25.7%)
Diabetes mellitus 0 (0%)
Rheumatoid arthritis 0 (0%)
Lupus 0 (0%)
Presenting signs and symptoms
Headache 10 (28.6%)
Seizure 6 (17.1%)
Other neurological finding 18 (51.4%)
Incidental 1 (2.9%)
Type of surgical resection






Pre-diagnosis cranial radiation 2 (5.7%)
Margin dose 18 Gy (14–24)
Tumor characteristics
Tumor volume 3.90 cm3 (0.19-33.1)
Treated tumor volume 3.90 cm3 (0.19-31.9)
History of previous benign meningioma 3 (8.6%)
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General patient survival outcomes
Kaplan-Meier and Cox proportional hazards models
were used to estimate survival curves and examine the
association between clinical, pathologic, and imaging
parameters for recurrence and overall survival. Post-
Gamma Knife recurrence was identified in 11 patients,
and 9 patients had died. The median time to recurrence
from Gamma Knife was 25.8 months (range: 0 – 113
months) and the median overall survival was 36 months
(range: 0 – 120 months). One and three-year overall
survival (OS) rates were 86.1% and 78.0% respectively.
One and three-year progression-free survival (PFS) rates
were 88.7% and 65.0%, respectively.
Patient outcomes based on WHO grade
To analyze the effect of WHO grade on outcomes, atypical
grade II meningiomas were compared with malignant
grade III meningiomas. WHO grade II 1 and 3-year OS
rates were 92.4% and 83.4% respectively. WHO grade II 1
and 3-year PFS rates were 95.7% and 70.1% respectively.
WHO grade III 1 and 3-year OS rates were both 33.3%.
WHO grade III 1 and 3-year PFS rates were both 0%.
WHO grade III histology was significantly associated with
decreased survival (HR: 5.52, p = 0.031) and increased re-
currence (HR: 31.9, p = 0.0057). The overall survival
curves of grade II and III patients are presented in Figure 1;
the progression-free survival curves of grade II and III pa-
tients are presented in Figure 2.
Patient outcomes based on known prognostic parameters
A summary of parameters significant for recurrence or
survival is presented in Table 2.
The histopathology of meningiomas was analyzed to
identify parameters that significantly impacted survival
and recurrence. Of the characteristics used to diagnose
meningiomas as aggressive, including high nuclear to
cytoplasmic ratio, increased cellularity, prominent nucle-
oli, spontaneous or geographic necrosis, sheet-like growth,
nuclear atypia, and increased mitotic rate, only necrosis,
nuclear atypia, and mitotic rate were significantly predict-
ive. On univariate analysis, the presence of nuclear atypia
in 11 patients was associated with increased recurrence
(HR: 4.63, p = 0.0150), as was spontaneous necrosis in 17
patients (HR: 5.43, p = 0.0309) and increasing mitotic rate
(HR: 1.18, p = 0.00742).
Parameters relating to patients’ medical histories that
affected their survival were identified using univariate
analysis. A prior history of benign meningioma in 3 pa-
tients was associated with both worse overall survival
(HR: 10.46, p = 0.0208) and increased recurrence (HR:
24.98, p = 0.00938). A prior history of fractionated radi-
ation therapy in 9 patients was associated with worse
overall survival (HR: 5.76, p = 0.0234). Increasing length
of time between surgery and Gamma Knife significantly
decreased overall survival (HR: 1.01, p = 0.0190), al-
though the clinical effect was small.
Parameters relating to the radiosurgery itself that signifi-
cantly affected survival were also examined. Increasing
margin dose of radiation was significantly associated with
recurrence (HR: 1.01, p = 0.00051), although again the clin-
ical effect was small. Overall survival was detrimentally im-
pacted by both higher tumor volume (HR: 1.08, p =
0.00812) and treated tumor volume (HR: 1.08, p = 0.00824).
Increasing the number of isocenters (HR 1.17, p = 0.00146)
Figure 1 Overall survival. Kaplan-Meier overall survival curve of WHO grade II (blue line) and grade III (red line) patients in months post-Gamma Knife.
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and the volume of each isocenter (HR: 1.04, p = 0.0106) ad-
versely affected overall survival.
Age at surgery and at the time of radiosurgery did
not have a significant impact on either survival or re-
currence in this cohort. The presence of bone or brain
invasion did not have a significant impact on either sur-
vival or recurrence, possibly because our cohort only
included one instance of bone invasion and seven of
brain invasion.
On multivariate analysis, the only significant factor
for recurrence was WHO grade II histology (HR: 0.047,
p = 0.0134), while the absence of spontaneous necrosis
had a trend towards increased survival (HR: 0.217, p =
0.0556). The only significant factors for overall survival
on multivariate analysis were WHO grade II histology
(HR: 0.168, p = 0.0386) and high treated tumor volume
(HR: 1.096, p = 0.0095).
Analysis of atypical (WHO grade II) meningiomas
In order to better identify prognostic factors of atyp-
ical meningiomas, an additional analysis of only the 31
WHO grade II patients was carried out. Significant prog-
nostic parameters are presented in Table 3. The median
time to recurrence post-Gamma Knife for this cohort was
27.5 months. The median survival post-Gamma Knife was
36.2 months.
On univariate analysis, the parameters significant for re-
currence in this cohort were bone invasion (HR: 16.43, p =
0.0480), pre-event radiation therapy (HR: 9.52, p = 0.0116),
and margin dose (HR: 1.01, p = 0.00151). On multivariate
analysis, margin dose was the only significant parameter for
recurrence (HR: 1.01, p = 0.0065).
The parameters significant for overall survival on uni-
variate analysis were a history of prior fractionated RT
(HR: 6.31, p = 0.0457), time from surgery to GK (HR: 1.01,
Figure 2 Progression-free survival. Kaplan-Meier progression-free survival curve of WHO grade II (blue line) and grade III (red line) patients in
months post-Gamma Knife.
Table 2 Significant prognostic factors for overall survival and recurrence
Overall survival Recurrence
Parameter Hazard ratio p value Parameter Hazard ratio p value
Prior history of benign meningioma 10.46 0.02075 Prior history of benign meningioma 24.9765 0.00938
Prior fractionated RT 5.76 0.0234 Necrosis 5.4325 0.03085
WHO grade III 5.52 0.03137 WHO grade III 31.8875 0.0057
Time from surgery to GK 1.01 0.01902 Nuclear atypia 4.6286 0.015
Isocenter volume 1.04 0.01058 Margin dose 1.0061 0.00051
Tumor volume treated 1.08 0.00824 Mitotic rate 1.1802 0.00742
Tumor volume 1.08 0.00812
Isocenter number 1.17 0.00146
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p = 0.0258), isocenter number (HR: 1.18, p = 0.0136) and
isocenter volume (HR: 1.05, p = 0.0122), tumor volume
(HR: 1.09, p = 0.00889), and treated tumor volume (HR:
1.10, p = 0.00879). On multivariate analysis, only treated
tumor volume was significant for overall survival in this
group (HR: 1.01, p = 0.0088).
Discussion
WHO grade II and III meningiomas are rare and heteroge-
neous tumors of the meninges. Their outcomes and rates
of recurrence can be difficult to predict. This complicates
the selection of an appropriate therapy. More precise and
accurate prognostic factors are needed in order to identify
tumors associated with recurrence and decreased survival.
Previous studies of WHO grade II and III meningiomas
have identified age, sex, WHO grade, tumor location, and
extent of resection as useful prognostic parameters [9].
Table 4 presents previously reported outcomes of aggressive
meningiomas treated by Gamma Knife radiosurgery.
The current study analyzed 35 patients with atypical
(WHO grade II) and malignant (WHO grade III) meningi-
omas who received Gamma Knife radiosurgery between
2000 and 2011. The purpose was to identify characteristics
that predict survival and recurrence, as well as to deter-
mine the overall and progression-free survival of patients
with aggressive meningiomas treated with radiosurgery at
our institution.
WHO grade is a well-known prognostic factor from
previous studies. Grade III meningiomas are typically
associated with poorer survival and higher rates of re-
currence [9,28]. However, a 2008 series of 119 grade II
and III meningioma patients treated with external beam
radiotherapy reported no significant differences in over-
all survival or disease-free survival based on WHO
grade [15]. Kondziolka et al. demonstrated that radiosur-
gery produces effective local control in benign meningi-
omas, but had worse outcomes for aggressive tumors.
They reviewed 384 grade I tumors and found a tumor
control rate of 93% at a median of 4 years. They found a
50% control rate in 54 grade II tumors at a median of 2
years, and a 15% control rate in 29 grade III tumors at a
median of 15 months [24].
A 2009 series of 199 aggressive meningioma patients
treated surgically found the 5- and 10- year OS rates of
grade II patients were 78.4% and 53.3% respectively [9].
The OS rates of grade III patients were 44.0% and 14.2%
respectively. The 5- and 10-year PFS rates for grade II
were 48.4% and 22.6% respectively, while for grade III they
were 8.4% and 0.0%.
In another analysis of aggressive meningiomas, Mori
et al. looked at 22 grade II and 4 grade III meningioma
patients undergoing Gamma Knife radiosurgery [26].
They found local tumor control after treatment was 74%
at 1 year, 52% at 2 years, and 34% at 3 years. Attia et al.
analyzed 24 patients with atypical meningiomas treated
with Gamma Knife radiosurgery as either primary or sal-
vage therapy and found local control rates at 1, 2, and 5
years of 75, 51, and 44% [25].
Among our patients, the 3-year OS rates were 84.1%
for grade II and 33.3% for grade III. The 3-year PFS rates
were 70.1% for grade II and 0.0% for grade III. These re-
sults agree with previous findings that WHO grade III
tumors are associated with poorer outcomes, although
there were only 4 grade III meningioma patients in our
series. Three-year OS and PFS rates overall were 78.0%
and 65.0%, respectively.
Histological features associated with aggressive meningi-
omas were also examined, such as hypercellularity, brain in-
vasion, elevated mitotic rate, prominent nucleoli, and cell
necrosis. Kim et al. found that anaplasia, mitotic index
≥20/10 high-power fields, subtotal tumor resection, loss of
short arm of chromosome 1 (1p-), and Ki-67 labeling index
>12% were independent predictors of recurrence [29].
Pasquier et al., in their 2008 series of 119 grade II and III
meningiomas treated with external beam radiotherapy, also
found that high mitotic rate adversely affected overall survival
and disease-free survival [15]. In our study, high mitotic rate,
spontaneous necrosis, and nuclear atypia were associated with
increased rates of recurrence on univariate analysis.
A retrospective analysis of 35 patients with 49 atypical
and anaplastic meningiomas treated with radiosurgery
found local tumor control rates for grade II meningiomas
at 1, 2 and 3 years after radiosurgery were 78, 53 and 36%,
respectively [30]. Grade III meningioma local control rates
Table 3 Significant prognostic factors in WHO grade II meningiomas alone
Overall survival Recurrence
Parameter Hazard ratio p value Parameter Hazard ratio p value
Prior fractionated RT 6.31 0.04572 Bone invasion 16.43 0.04801
Time from surgery to GK 1.01 0.02578 Pre-event RT 9.52 0.01157
Isocenter number 1.18 0.01361 Margin dose 1.01 0.00151
Isocenter volume 1.05 0.01222
Tumor volume 1.09 0.00889
Treated tumor volume 1.1 0.00879
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Table 4 Literature review of aggressive meningiomas treated by gamma knife




Max dose (Gy) Control rate Progression
free survival
Overall survival Statistically significant prognostic
factors on multivariate analysis
Ojemann et al., 2000 [20] 3 19 (31) Mean 16 18 5 year 26% 5 year 40% PFS and OS: age (p < 0.003),
tumor volume (p < 0.05)
Stafford et al., 2001 [21] 2 13 Median 16 36 5 year 68% 5 year 76%*
3 9 5 year 0% 5 year 0%*
Harris et al., 2003 [22] 2 18 Mean 14.9 29.4 5 year 83% 5 and 10 year 59% PFS: early SRS (p < 0.001),
small tumor volume (p < 0.001)
3 12 Mean 15.7 31.4 5 year 72% 5 year 59% 10 year 0% OS: younger age (p = 0.03)
Huffmann et al., 2005 [23] 2 15 (21) 18 6 months 93% 100% at median follow
up of 35 months
Kondziolka et al., 2008 [24] 2 54 50% at median
of 2 years
3 29 17% at median of
15 months
Attia et al., 2012 [25] 2 24 Median 14 18 1 year 75% 2 year 40% 1 year 92% PFS: dose > 14 Gy (p = 0.01)
2 year 51% 5 year 25% 2 year 67%
5 year 44% 5 year 52%
Mori et al., 2013 [26] 2 19 (22) Mean 16.5 20.15 1 year 74%,
3 4 2 year 54%,
3 year 34%
Tamura et al., 2013 [27] 2 9 Mean 18.8 37 Stabilization of tumor growth: small
lesion volume (p = 0.02), marginal dose
(p = 0.04), max dose (p = 0.02)3 7
Current series 2 31 Median 18 24 1 year 95.7%
3 year 70.1%
1 year 92.4% 3
year 83.4%
Recurrence: WHO grade 2
histology (p = 0.0134)
3 4 1 and 3 year 0% 1 and 3 year 33.3% OS: WHO grade 2 histology (p = 0.0386),

















were 35% at 1 year and 10% at 2 years. Multivariate analysis
indicated that the mitotic count and the MIB-1 prolifera-
tion marker labeling index were significant prognostic
factors.
We did not find prominent nucleoli, sheeting, high nu-
cleus to cytoplasm ratio, hypercellularity, frank anaplasia,
bone invasion, or brain invasion to be associated with
either survival or recurrence, although bone invasion was
significant for recurrence on univariate analysis among the
WHO II meningiomas alone. This may be affected by the
relatively low prevalence of bone invasion (1 instance) and
brain invasion (7 instances) in this series, as well as the
low number of grade III meningiomas.
Age under 60 at diagnosis has been identified as a pre-
dictor of better outcomes among aggressive meningioma
patients [9,15]. We did not find either age at initial sur-
gery or age at radiosurgery to be a significant parameter
for survival or recurrence in our series.
Gross total resection has also been identified in previous
studies as a favorable prognostic parameter [15,29]. In an
analysis of 199 aggressive meningiomas treated surgically,
Durand et al. found that age under 60, Simpson grade I re-
section, and grade II histology were independent prognostic
factors for survival on multivariate analysis [9]. However
our study did not find that the extent of resection was pre-
dictive of recurrence or overall survival.
The three patients in our series with a prior history of
benign meningioma exhibited strong associations with
recurrence (HR 25.0, p = 0.021) and poor survival (HR
10.5, p = 0.0094). This suggests that benign meningiomas
may be more dangerous than realized, as patients who
subsequently develop atypical or malignant meningi-
omas have a more aggressive course. We also found that
patients who had undergone previous fractionated radio-
therapy had worse overall survival on univariate analysis
(HR: 5.76, p = 0.0234). This may simply reflect that these
patients had a more aggressive or difficult course that
therefore received more and earlier treatment.
An increasing length of time between surgery and
Gamma Knife was statistically associated with worse over-
all survival, but the effect was so small (HR 1.01, p =
0.019) that this is unlikely to be clinically significant.
Tumor size was significantly associated with worse
overall survival in our series. Larger tumor volumes and
treated tumor volumes were both associated with poor
survival, but not increased recurrence. Larger tumors
are at a greater risk of herniation, leading to higher
mortality rates. These results agree with other studies
that have shown that among benign meningiomas
treated with Gamma Knife, larger tumors are associated
with significantly worse 5-year disease-free survival and
tumor control [31,32]. Tamura et al. analyzed 9 grade II
and 7 grade III meningiomas and found that small le-
sion volume, as well as greater marginal and maximum
irradiation doses, were associated with stabilization of
tumor growth [27].
The strongest association in our series was between
WHO grade III histology and recurrence (HR 31.9, p =
0.0057). Interestingly, the individual histological features
used to determine WHO grade were either not significant
or considerably less significant. Nuclear atypia (HR 4.63,
p = 0.015), necrosis (HR 5.43, p = 0.031), and high mitotic
rate (HR 1.18, p = 0.0074) were significant for recurrence.
The other histological features were not significant for
either recurrence or survival. This suggests that it is the
combination of individual features, rather than any one
factor, that determines prognosis, and strengthens the
credibility of the WHO grading criteria. WHO grade III
meningiomas were also strongly associated with worse
overall survival (HR 5.52, p = 0.031), although not to the
same degree as recurrence. On multivariate analysis,
WHO grade II diagnosis was the only significant favorable
prognostic factor for recurrence (HR: 0.047, p = 0.0134).
WHO grade II diagnosis (HR: 0.168, p = 0.0386) and larger
tumor volume treated (HR: 1.096, p = 0.0095) were the
only significant prognostic factors for decreased overall
survival on multivariate analysis.
When analyzing WHO grade II meningiomas alone, the
most significant parameters for overall survival were iso-
center number, isocenter volume, tumor volume, and
treated tumor volume, which were all highly correlated
with each other and largely reflect tumor size. On multi-
variate analysis of WHO II tumors alone, increased tumor
volume treated was the only parameter significant for de-
creased overall survival (HR 1.01 and p = 0.0088). A his-
tory of prior fractionated radiation therapy and increasing
length of time between surgery and radiosurgery were also
significantly associated with worse overall survival on uni-
variate analysis.
Bone invasion (HR 16.43, p = 0.048) and pre-event ra-
diation therapy (HR 9.52, p = 0.01157) were significantly
associated with recurrence on univariate analysis among
the WHO II tumors alone.
Increasing margin dose was significantly associated with
increased recurrence among grade II meningioma patients
(HR 1.01, p = 0.0015). It was also the only significant vari-
able for recurrence on multivariate analysis (HR 1.01, p =
0.0065). This most likely reflects that the tumors at high-
est risk of recurrence were correctly identified and there-
fore given a higher dose, although the increase in risk was
quite small. Attia et al. have found that dose > 14 Gy was
significantly associated with improved PFS on multivariate
analysis in atypical meningioma patients treated with ra-
diosurgery [25].
Conclusion
These results indicate that WHO grade III diagnosis is
the strongest predictor of recurrence and mortality in
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aggressive meningioma patients treated with surgery and
Gamma Knife. It was the only parameter significant on
multivariate analysis for both recurrence and survival.
Larger tumors were associated with worse survival in
our series, while nuclear atypia, necrosis, and increased
mitotic rate were risk factors for recurrence. This study
suggests that Gamma Knife radiosurgery is a useful ad-
junctive therapy to surgery in the treatment of aggressive
and recurrent meningiomas. The patients most likely to
benefit are those with smaller tumors. This study is lim-
ited by its retrospective nature and small subject pool.
Additional higher-powered studies analyzing survival
and recurrence in a larger cohort are needed to identify
risk factors with a smaller clinical effect.
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